Prior studies describe ARRDC3 as a tumor suppressor in other cancers, where it attenuates GPCR signaling and limits invasion, and additional evidence links ARRDC3 polymorphisms and expression to glioma susceptibility and adverse outcomes in related malignancies (39, 40). This evidence concerns the gene ARRDC3 and central nervous system cancer.